Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

Everolimus (Eve) is an FDA approved drug that inhibits mammalian target of rapamycin (mTOR). It is employed in breast cancer treatment even if its responsiveness is controversial. In an attempt to increase Eve effectiveness, we have developed a novel Eve nanoformulation exploiting H-ferritin nanocag...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Pharmaceutics
Huvudupphovsmän: Bonizzi, Arianna, Truffi, Marta, Sevieri, Marta, Allevi, Raffaele, Sitia, Leopoldo, Ottria, Roberta, Sorrentino, Luca, Sottani, Cristina, Negri, Sara, Grignani, Elena, Mazzucchelli, Serena, Corsi, Fabio
Materialtyp: Artigo
Språk:Inglês
Publicerad: MDPI 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6723888/
https://ncbi.nlm.nih.gov/pubmed/31382388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmaceutics11080384
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk